Tumor PD-L1 expression status is closely associated with the effectiveness of anti-PD-1/PD-L1 immunotherapy, and it is widely used as a feasible molecular biomarker for treatment efficacy prediction [11]. The gene discussed is CD274; the disease is neoplasm.